Literature DB >> 24971173

Comparison of Postprandial Responses to a High-Fat Meal in Hypertriglyceridemic Men and Women before and after Treatment with Fenofibrate in the Genetics and Lipid Lowering Drugs and Diet Network (GOLDN) Study.

Stephen P Glasser1, Mary K Wojczynski2, A I Oberman1, Edmond K Kabagambe2, Michael Y Tsai3, Jose M Ordovas4, Robert J Straka5, Donna K Arnett2.   

Abstract

CONTEXT: The fenofibrate effect on the subclass size distribution of lipoproteins before and after a high-fat challenge is not well studied.
OBJECTIVE: To characterize the baseline and post-prandial response (PPL) to a high-fat challenge following fenofibrate therapy, on changes in LDL, HDL, and VLDL particle subclasses, number, and size in 271 hypertriglyceridemic participants.
METHODS: Participants from the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) study who conducted PPL studies both before and after three weeks of fenofibrate (160 mg/d) treatment were analyzed. Particle size distributions were determined using nuclear magnetic resonance imaging, and lipid determinations were measured at fasting (0 hr), 3.5 hours, and 6 hours after ingestion of a standardized high-fat meal. Analyses were stratified by gender. Changes in particle subclass distributions were assessed using repeated measures analysis of variance adjusted for pedigree.
RESULTS: Before PPL, fenofibrate in men (adjusted for age, field center, smoking status, diabetes, and weight circumference) lowered fasting and postprandial VLDL primarily due to reductions in postprandial levels of large and medium VLDL particles (9 SE +/-0.7 to 4 +/-0.4 and 78 / -4 to 36 / -3 nmol/L both P < .0001, resp.). Fenofibrate also reduced fasting and postprandial total LDL particles, primarily a result of reduced small LDL particles (1497 = / - 37 to 1088 = / - 36 nmol/L, P < .0001). Directional changes were similar in men and women but the magnitude of change was different for some parameters.
CONCLUSION: Fenofibrate treatment resulted in a lower triglyceride excursion following a high-fat meal. This investigation provides new knowledge of the magnitude and time course of fenofibrate induced attenuation of Lipoprotein subclass size distribution following a postprandial lipid challenge.

Entities:  

Year:  2010        PMID: 24971173      PMCID: PMC4067904          DOI: 10.3814/2010/485146

Source DB:  PubMed          Journal:  SRX Pharmacol        ISSN: 2090-1151


  25 in total

1.  Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk.

Authors:  M A Austin; M C King; K M Vranizan; R M Krauss
Journal:  Circulation       Date:  1990-08       Impact factor: 29.690

Review 2.  Lipid triad or atherogenic lipoprotein phenotype: a role in cardiovascular prevention?

Authors:  Manfredi Rizzo; Kaspar Berneis
Journal:  J Atheroscler Thromb       Date:  2005       Impact factor: 4.928

3.  Characterization of human high-density lipoproteins by gradient gel electrophoresis.

Authors:  P J Blanche; E L Gong; T M Forte; A V Nichols
Journal:  Biochim Biophys Acta       Date:  1981-09-24

4.  A 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients.

Authors:  Isabelle Lemieux; Luc Laperrière; Vladimir Dzavik; Gérald Tremblay; Joanne Bourgeois; Jean Pierre Després
Journal:  Atherosclerosis       Date:  2002-06       Impact factor: 5.162

5.  Fenofibrate decreases plasma fibrinogen, improves lipid profile, and reduces uricemia.

Authors:  G de la Serna; C Cadarso
Journal:  Clin Pharmacol Ther       Date:  1999-08       Impact factor: 6.875

6.  Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state.

Authors:  J R Patsch; G Miesenböck; T Hopferwieser; V Mühlberger; E Knapp; J K Dunn; A M Gotto; W Patsch
Journal:  Arterioscler Thromb       Date:  1992-11

7.  High density lipoproteins and coronary atherosclerosis. A strong inverse relation with the largest particles is confined to normotriglyceridemic patients.

Authors:  J Johansson; L A Carlson; C Landou; A Hamsten
Journal:  Arterioscler Thromb       Date:  1991 Jan-Feb

8.  The -256T>C polymorphism in the apolipoprotein A-II gene promoter is associated with body mass index and food intake in the genetics of lipid lowering drugs and diet network study.

Authors:  Dolores Corella; Donna K Arnett; Michael Y Tsai; Edmond K Kabagambe; James M Peacock; James E Hixson; Robert J Straka; Michael Province; Chao-Qiang Lai; Laurence D Parnell; Ingrid Borecki; Jose M Ordovas
Journal:  Clin Chem       Date:  2007-04-19       Impact factor: 8.327

9.  Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events.

Authors:  Samia Mora; Nader Rifai; Julie E Buring; Paul M Ridker
Journal:  Circulation       Date:  2008-08-18       Impact factor: 29.690

10.  Alterations in the concentration of an apolipoprotein E-containing subfraction of plasma high density lipoprotein in coronary heart disease.

Authors:  H M Wilson; J C Patel; D Russell; E R Skinner
Journal:  Clin Chim Acta       Date:  1993-11-15       Impact factor: 3.786

View more
  2 in total

1.  Fibrate pharmacogenomics: expanding past the genome.

Authors:  John S House; Alison A Motsinger-Reif
Journal:  Pharmacogenomics       Date:  2020-03-17       Impact factor: 2.533

2.  An exome-wide sequencing study of lipid response to high-fat meal and fenofibrate in Caucasians from the GOLDN cohort.

Authors:  Xin Geng; Marguerite R Irvin; Bertha Hidalgo; Stella Aslibekyan; Vinodh Srinivasasainagendra; Ping An; Alexis C Frazier-Wood; Hemant K Tiwari; Tushar Dave; Kathleen Ryan; Jose M Ordovas; Robert J Straka; Mary F Feitosa; Paul N Hopkins; Ingrid Borecki; Michael A Province; Braxton D Mitchell; Donna K Arnett; Degui Zhi
Journal:  J Lipid Res       Date:  2018-02-20       Impact factor: 5.922

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.